Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Negotiation List Surprises Highlight The Importance Of Current Spending Data

Executive Summary

Some drugs recorded significant increases in Medicare gross spending between the periods covered by publicly available data and what CMS had access to internally, which contributed to their unexpected presence on the list.

You may also be interested in...



A Reasonable Approach To ‘Reasonable Pricing’?

Biopharma companies are preparing to fight a new Biden Administration proposal to allow price to be a factor in invoking ‘March In’ rights on US government funded patents. However, an argument can be made that the new framework would be better than the status quo.

Price Caps In Regeneron’s COVID Monoclonal Deal With HHS: Not A Precedent, But Enough For Bernie

As FDA clears new COVID vaccines, the Regeneron deal is a reminder of the politics of drug pricing. Sen. Sanders touts the agreement, which attaches product price caps to funding for clinical development, and he allows the confirmation effort for the NIH director nominee to proceed.

US Price Negotiation Pioneers: The Unique Position Of Imbruvica

The first 10 drugs picked for price negotiation in the US Medicare program will all be unwilling trailblazers. But the position of Abbvie’s Imbruvica stands out as unique in several important ways.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS148781

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel